Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238307 | 0.86 | GAA (0.34) | TDP1ALDH1A1GAAHTTRECQL | |
| SCHEMBL11600655 | 0.80 | ALDH1A1 (0.39) | ALDH1A1FFAR3GAAHTTRECQL | |
| SCHEMBL11480859 | 0.77 | CYP2C19 (0.45) | TDP1ALDH1A1GAAHTTRECQL | |
| SCHEMBL10625547 | 0.77 | — | — | |
| SCHEMBL4483900 | 0.77 | TDP1 (0.43) | TDP1ALDH1A1FFAR3SOAT1 | |
| SCHEMBL19057078 | 0.77 | — | — | |
| SCHEMBL28378728 | 0.76 | ALDH1A1 (0.38) | ALDH1A1GAAHTTRECQLL3MBTL1 | |
| SCHEMBL2915579 | 0.75 | GAA (0.37) | GAAHTTRECQLNPC1L3MBTL1 | |
| SCHEMBL10211016 | 0.75 | GAA (0.44) | ALDH1A1GAAHTTRECQLL3MBTL1 | |
| SCHEMBL2910108 | 0.73 | GAA (0.54) | TDP1ALDH1A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0251408-B1 | NOVEL ANTI-INFLAMMATORY AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | THE PROCTER & GAMBLE COMPANY (US) | 1991-04-17 | — | — | EP | claimed |
| US-9422247-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-08-23 | — | — | US | disclosed |
| US-9422247-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-08-23 | — | — | US | disclosed |
| US-9422247-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-08-23 | — | — | US | disclosed |
| EP-2691376-B1 | FE(III) COMPLEXES FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANAEMIAS | VIFOR INT AG (CH) | 2015-12-09 | — | — | EP | disclosed |
| US-20140162994-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2014-06-12 | — | — | US | disclosed |
| US-20140162994-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2014-06-12 | — | — | US | disclosed |
| US-20140162994-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2014-06-12 | — | — | US | disclosed |
| EP-2691376-A1 | FE(III) COMPLEXES FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANAEMIAS | Vifor (International) AG (CH) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012130882-A1 | FE(III) COMPLEXES FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANAEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2012-10-04 | — | — | WO | disclosed |
| EP-1601659-B1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2008-01-16 | — | — | EP | disclosed |
| EP-1826202-A1 | Process for the preparation of furan compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-20070197806-A1 | Process for the preparation of furan compounds | DAICEL CHEMICAL INDUSTRIES, LTD. | 2007-08-23 | — | — | US | disclosed |
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ABBOT GMBH & CO. KG (DE) | 2006-10-19 | — | — | US | disclosed |
| EP-1601659-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080981-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2004-09-23 | — | — | WO | disclosed |
| US-4252946-A | BACTERICIDES, FUNGICIDES, ANTIPROTOZOA AGENTS | BURROUGHS WELLCOME CO. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4229456-A | SUPPRESSION OF GASTRIC SECRETIONS | MERCK & CO., INC. (US) | 1980-10-21 | — | — | US | disclosed |
| US-4133885-A | GASTRIC SECRETIONS INHIBITORS | MERCK & CO., INC. (US) | 1979-01-09 | — | — | US | disclosed |
| US-4113859-A | ANTIBACTERIAL, ANTIPROTOZOAL, ANTIFUNGAL AGENTS | BURROUGHS WELLCOME CO. (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197806-A1 | Process for the preparation of furan compounds | CBR1, CBR3, POR | TDP1 4098/4885ALDH1A1 160/4885FFAR3 193/4885 |
| US-20140162994-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | FECH, SDHB, SLC40A1 | TDP1 4796/4885ALDH1A1 1539/4885FFAR3 2936/4885 |
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ADRB3, DRD3, OPRL1 | TDP1 3665/4885ALDH1A1 1158/4885FFAR3 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.